Neugenesis Corporation Announces the Retirement of Ronald E. Cape as Chairman of its Board of Directors
Published: Jan 27, 2009
BURLINGAME, Calif.--(BUSINESS WIRE)--Neugenesis Corporation, a company with proven and proprietary technology for rapid and inexpensive production and improvement of multivalent vaccines for infectious diseases and other high value biopharmaceutical drugs including monoclonal antibodies today announced that Ronald E. Cape has resigned his appointment as the company’s Chairman of the Board. Dr. Cape has been Chairman of Neugenesis since 1995, and has been instrumental in helping the Company chart its path forward from a small start up to a thriving development stage organization with bio-defense contracts from the Federal Government. Dr. Cape was the co-founder, Chairman and CEO of Cetus Corporation, a world leader and pioneer in genetic engineering, including the discovery and development of the polymerase chain reaction (PCR), for which Cetus scientist Kary Mullis received the Nobel Prize. Cetus later merged with Chiron Corporation. Dr. Cape was the founding chairman of Darwin Molecular Corporation, which was later sold to Chiroscience plc. He was also a founding member of the Biotechnology Industry Organization and served as its President for three years.